Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Obstetrics and Gynaecology
  • Obstetrics and Gynaecology News
  • Study Decodes...

Study Decodes Deescalation: Impact of BRCA Pathogenic Variants on Neoadjuvant Treatment in Triple-Negative Breast Cancer

Written by Dr Pooja N. Published On 2025-04-22T20:45:16+05:30  |  Updated On 22 April 2025 8:45 PM IST
Breast Cancer
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

Recent investigation focuses on the effects of BRCA1 and BRCA2 tumor pathogenic variants (tPVs) within the parameters of two deescalated neoadjuvant chemotherapy regimens—nab-paclitaxel combined with either carboplatin or gemcitabine—on key outcomes, specifically pathologic complete response (pCR), invasive disease-free survival (IDFS), and overall survival (OS) in early-stage triple-negative breast cancer (TNBC) patients. This analysis is centered on a phase 2 randomized clinical trial, ADAPT-TN, conducted across 45 sites in Germany.

DNA Sample Analysis

Out of 307 available DNA samples collected from pretreatment biopsies, successful sequencing was achieved for 266 patients due to low DNA amounts and quality control failures in some samples. The cohort comprised entirely of female patients with a median age of 51 years. Investigators found that the association between pCR rates and survival outcomes, particularly IDFS, was crucial. While TP53 tPVs did not markedly impact pCR, there was a trend indicating that PIK3CA tPVs could be deleterious, although results were not statistically significant.

Challenges in TNBC Treatment

The study underscores the ongoing challenges in treating TNBC due to its aggression and the lack of effective therapeutic targets. The prevalence of germline pathogenic variants in BRCA1/2 ranges from 9% to 18% among unselected TNBC patients, implying a significant link between hereditary factors and treatment response. Notably, previous studies noted superiority in pCR rates and disease-free survival when carboplatin is included in therapy.

Trial Methods and Outcomes

In the ADAPT-TN trial, patients were randomly assigned to receive either nab-paclitaxel with carboplatin or nab-paclitaxel with gemcitabine for 12 weeks. A statistically significant improvement in pCR rates was observed in the carboplatin group (45.9%) compared to the gemcitabine group (28.7%). Importantly, the enhanced pCR rates did not translate to improved 5-year IDFS or OS, suggesting that while pCR serves as a critical marker for response, it does not automatically guarantee better long-term outcomes.

BRCA1/2 tPV Status Insights

A significant aspect of the findings is the potential role of BRCA1/2 tPV status in determining which patients may benefit from carboplatin. Within the smaller subgroup of patients with BRCA1/2 tPVs treated with carboplatin, there was a notable pCR rate of 64.3%, which is promising compared to the BRCA1/2 wild-type group (24.6%). Despite these encouraging results, the impacts on long-term survival rates for this cohort were not statistically significant and require further investigation.

Survival Outcomes and Trends

Additionally, survival outcomes indicated a concerning trend for patients with PIK3CA tPVs showing poorer survival rates compared to those with wild-type status, aligning with existing literature linking PIK3CA mutations to chemotherapy resistance. Conversely, patients without TP53 tPVs exhibited better survival outcomes, a finding echoed in previous studies.

Analysis Limitations

The exploratory nature of this secondary analysis highlights several limitations. The small sample sizes within genetic subgroups resulted in insufficient statistical power, which hinders definitive conclusions. Furthermore, survival was a secondary endpoint of the primary trial, complicating the interpretation of the survival data. In conclusion, while deescalated neoadjuvant nab-paclitaxel plus carboplatin appears effective, the role of BRCA1/2 tPVs presents a promising avenue for further research. The study advocates for larger trials that can focus on survival endpoints to better delineate the potential benefits of chemotherapy deescalation based on genetic profiling. This research heralds the necessity of precision medicine in refining treatment strategies for TNBC.

Key Points

-- -*-*Investigation Focus-*-*: The study evaluates the impact of BRCA1 and BRCA2 tumor pathogenic variants (tPVs) on outcomes of de-escalated neoadjuvant chemotherapy regimens, specifically comparing nab-paclitaxel combined with carboplatin versus gemcitabine, in early-stage triple-negative breast cancer (TNBC) patients. Key outcomes assessed include pathologic complete response (pCR), invasive disease-free survival (IDFS), and overall survival (OS).

- -*-*DNA Sample Insights-*-*: Out of 307 collected DNA samples from pretreatment biopsies, 266 were successfully sequenced. The patient cohort, consisting entirely of women with a median age of 51 years, showed a crucial relationship between pCR rates and survival outcomes, particularly IDFS. While TP53 tPVs had minimal effects on pCR, there was a suggestive trend toward deleterious implications of PIK3CA tPVs, although not statistically significant.

- -*-*Challenges and Prevalence-*-*: The investigation emphasizes the treatment challenges posed by TNBC's aggressiveness and the dearth of effective therapeutic targets. It notes that 9% to 18% of unselected TNBC patients carry germline pathogenic variants in BRCA1/2, highlighting the hereditary link to treatment responses. Prior studies have suggested improved pCR rates and disease-free survival with carboplatin inclusion in therapy.

- -*-*Trial Design and Results-*-*: In the ADAPT-TN trial, patients were randomly assigned to nab-paclitaxel with either carboplatin or gemcitabine for 12 weeks. Results indicated a significant improvement in pCR rates within the carboplatin group (45.9%) compared to the gemcitabine group (28.7%). However, this increase did not correlate with improved 5-year IDFS or OS, indicating that pCR alone does not ensure better long-term outcomes.

- -*-*BRCA1/2 tPV Impact-*-*: The analysis suggests that the BRCA1/2 tPV status may identify patients who would particularly benefit from carboplatin, as evidenced by a pCR rate of 64.3% in the BRCA1/2 tPV subgroup compared to 24.6% in the wild-type group. However, differences in long-term survival rates for this group were not statistically significant and warranted further exploration.

- -*-*Limitations and Future Directions-*-*: The exploratory nature of the analysis identifies limitations such as small genetic subgroup sample sizes affecting statistical power and the secondary endpoint nature of survival data. It calls for larger trials focusing on survival outcomes to better understand the implications of chemotherapy deescalation based on genetic profiles, emphasizing the need for precision medicine in TNBC treatment strategies.

Reference –

Lisa Richters et al. (2025). Genetic Alterations, Therapy Response, And Survival Among Patients With Triple-Negative Breast Cancer. *JAMA Network Open*, 8. https://doi.org/10.1001/jamanetworkopen.2024.61639.


BRCA1BRCA2neoadjuvant treatmenttriple-negative breast cancer
Dr Pooja N.
Dr Pooja N.

    She has done her MBBS and later DGO. She is working as a private practitioner.

    Show Full Article
    Next Story

    Editorial

    ABYSS Trial Finds Elevated BP, HR & Deleterious CV Outcomes After Beta blocker Withdrawal Post-MI: EuroPCR 2025 Update

    ABYSS Trial Finds Elevated BP, HR & Deleterious CV Outcomes After Beta blocker Withdrawal Post-MI:...

    Aspirin Use in Male Smokers Aged 40-45 Years with Hypertension: Identifying the Ideal Candidates

    Aspirin Use in Male Smokers Aged 40-45 Years with Hypertension: Identifying the Ideal Candidates

    National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

    National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

    Relevance of Pioglitazone in Indian T2DM Care Continuum

    Relevance of Pioglitazone in Indian T2DM Care Continuum

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    View All

    Journal Club Today

    Study Unveils Molecular Links between Air Pollution and Negative Birth Outcomes

    Study Unveils Molecular Links between Air Pollution and Negative Birth Outcomes

    View All

    Health News Today

    Health Bulletin 06/June/2025

    Health Bulletin 06/June/2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok